DIA
30.1.2024 10:01:28 CET | Business Wire | Press release
DIA, a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024, to be held March 12-14 at Square Brussels Convention Centre in Brussels.
DIA Europe, the largest and most forward-looking neutral healthcare conference on the continent, is the only event that gives representatives from the European Commission, the European Medicines Agency (EMA), the World Health Organization (WHO), the Heads of Medicines Agencies (HMA), national competent authorities, healthcare professionals, and patient populations the opportunity to come together to shape key policy decisions.
Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development. Panelists will explore optimal sustainability practices with more than 250 guest speakers across 11 rich content tracks that comprise 100-plus sessions, including much-anticipated "DIAmond sessions" and town halls. They will also participate in collaboration hubs, showcases, and workshops designed to drive change and innovative thinking.
"Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India. "No organization can tackle it alone, but through open dialogue, partnership across industry, government, and academia, and listening to the patient's perspective, we can drive real progress. Learning from each other will empower us to develop new approaches that benefit patients, society, and our planet."
Attendees will hear from more than 25 EMA executives, including Emer Cooke, the Executive Director of the EMA and the Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA); Martin Harvey Allchurch, the EMA's Head of International Affairs; and Dr. Peter Arlett, the EMA's Head of Data Analytics and Methods Task Force.
Leda Stott, a Senior Research Fellow at the Innovation and Technology for Development Centre at the Technical University of Madrid and an authority on multi-stakeholder collaboration; Veronique Toully, the Global Head of Sustainability, Corporate Affairs and Risks at UCB; and Dr. Glenn Wells, Chief Partnerships Officer at the Medicines and Healthcare Products Regulatory Agency (MHRA), will deliver a keynote address that examines healthcare's most pressing sustainability challenges.
Other can't-miss sessions include:
— "EU Regulatory Town Hall: The New Pharmaceutical Legislation": Explore how we are increasing availability and access to novel healthcare solutions.
— "Digital Transformation in the EU Regulatory Space": Discuss how Europe is building the foundations for its digital transformation in the regulatory space for the next 10 years.
— "Complexity: Interplay and Interface of Different Legislations": Learn how we can drive medicine research, development, and manufacturing amid an increasingly complicated landscape of EU policies and regulations.
Three new content tracks this year will cover emerging trends in healthcare: Artificial Intelligence, Data Science, and Real-World Evidence; Innovative Therapies, Precision Medicine, and Diagnostics; and International Collaboration and Regional Updates.
DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.
At DIA Europe, everyone meets on equal terms. To register to attend as a participant or media member, visit https://www.diaglobal.org/Flagship/DIA-Europe-2024.
About DIA
DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130133798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
Tigo Energy Improves Installer Choice via Fronius Compatibility with TS4 Product Line22.10.2026 18:02:00 CEST | Press release
Compatibility between Tigo MLPE and multiple Fronius inverter families gives solar installers worldwide greater flexibility to design high-quality systems with the features customers want. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a manufacturer declaration of compatibility from Fronius International GmbH, documenting compatibility between Tigo Flex MLPE products and multiple Fronius inverter families. The letter covers Tigo TS4-A-F, TS4-A-2F, TS4-A-O, and TS4-X-O products and the Fronius Primo GEN24, Primo GEN24 208-240, Symo GEN24, Verto, Tauro, and Tauro ECO inverter families, when configured according to the requirements specified by Fronius and Tigo. Building on established compatibility in Europe, the declaration extends manufacturer-confirmed compatibility to markets worldwide, including the United States and Canada, giving solar professionals greater flexibility to design high-q
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom